Product Description: TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep[1].
Applications: Neuroscience-Neuromodulation
Formula: C22H21F3N4O2
References: [1]Yang Z Q, et al. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents[J]. ACS Medicinal Chemistry Letters, 2010, 1(9): 504-509.
CAS Number: 1146395-46-1
Molecular Weight: 430.42
Research Area: Neurological Disease
Solubility: 10 mM in DMSO
Target: Calcium Channel